A Phase 1/2 interventional study of acalabrutinib and rituximab (IV) in Non Hodgkin Lymphoma, sponsored by Acerta Pharma BV. Active, not recruiting at 29 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Lymphoma, Non-Hodgkin by AstraZeneca — 3 open to participants now, 6 under way, 2 of them phase 3. Lymphoma, Non-Hodgkin · AstraZeneca.
Among the 19 studies in Lymphoma, Non-Hodgkin by AstraZeneca, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2014, is one of 6 in phase 1/2, and was the 8th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →3 of the 19 studies in Lymphoma, Non-Hodgkin by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Australia, China and 5 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 13 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 8 more countries
Ages 12+
By country, each count listing its studies:
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 10 · Phase 3 3
First in 2005; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 51 across the 18 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
2 of the studies in Lymphoma, Non-Hodgkin by AstraZeneca that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02972840Phase 3Acerta Pharma BVA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | 2027-02-15 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Lymphoma, Non-Hodgkin by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.
Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR.
Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed MZL including splenic, nodal, and extranodal sub-types
Subjects with gastric mucosa-associated lymphoid tissue (MALT) lymphoma must be Helicobacter pylori (HP)-negative
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
acalabrutinib Regimen 1 for relapsed, refractory Follicular Lymphoma subjects
Drug: acalabrutinib
acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive Follicular Lymphoma subjects
Drug: acalabrutinib · Drug: rituximab (IV)
acalabrutinib Regimen 1 for relapsed, refractory Marginal Zone Lymphoma subjects
Drug: acalabrutinib
acalabrutinib Regimen 2 + rituximab for relapsed, refractory Marginal Zone Lymphoma subjects
Drug: acalabrutinib · Drug: rituximab (IV)
acalabrutinib Regimen + lenalidomide + rituximab for relapsed, refractory Follicular Lymphoma subjects
Drug: acalabrutinib · Drug: rituximab (IV) · Drug: Lenalidomide
Also known as: ACP-196
Part 1: Incidence of Treatment-emergent Adverse Events.
Treatment-emergent adverse events were used to characterize the safety profile of acalabrutinib alone or in combination with rituximab in participants with relapsed/refractory follicular lymphoma (R/R FL).
Time frame: From the first dose of study drug until study discontinuation, 30 days after the last dose of study drug or one day before the first subsequent anticancer therapy, whichever was earlier, up to 80.7 months (the maximum participant's time on this study).
Part 2: Investigator Assessed Objective Response Rate (ORR) According to the Lugano Classification for Non-Hodgkin Lymphoma (NHL).
The objective response rate (ORR) is used to characterize the activity of acalabrutinib alone or in combination with rituximab in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).
Time frame: Based on all response assessments since the first dose of study drug until study discontinuation or the initiation of subsequent anticancer therapy, whichever was earlier, up to 65.1 months (the maximum participant's time on this study).
Part 3: Incidence of Treatment-emergent Adverse Events.
Treatment-emergent adverse events were used to characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in participants with relapsed/refractory follicular lymphoma (R/R FL).
Time frame: From the first dose of study drug until study discontinuation, 30 days after the last dose of study drug or one day before the first subsequent anticancer therapy, whichever was earlier, up to 54.3 months (the maximum participant's time on this study).
| Milestone | P1: RR Acalabrutinib 100 mg BID | P1: RR Acalabrutinib 100 mg BID + Rituximab | P1: RR Acalabrutinib 200 mg QD | P1: TN Acalabrutinib 100 mg BID + Rituximab | P2: Acalabrutinib | P2: Acalabrutinib + Rituximab | P3: Acalabrutinib + Rituximab + Lenalidomide 15 mg | P3: Acalabrutinib + Rituximab + Lenalidomide 20 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 12 | 13 | 2 | 13 | 43 | 1 | 8 | 21 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 12 | 13 | 2 | 13 | 43 | 1 | 8 | 21 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 7 | 0 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 3 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 4 | 3 | 0 | 3 | 2 |
| Withdrew: - disease progression | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: - subject started alternative cancer therapy | 7 | 6 | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: - study terminated by sponsor | 2 | 3 | 0 | 5 | 32 | 0 | 4 | 13 |
| Withdrew: - enrolled into follow-up study | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: - other | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Treatment-emergent adverse events were used to characterize the safety profile of acalabrutinib alone or in combination with rituximab in participants with relapsed/refractory follicular lymphoma (R/R FL).
| Number of participants | Part 1: Acalabrutinib 100 mg BID | Part 1: Acalabrutinib 100 mg BID + Rituximab | Part 1: Relapsed or Refractory Acalabrutinib 200 mg QD | Part 1: Acalabrutinib 100 mg Rituximab |
|---|---|---|---|---|
| Part 1: Incidence of Treatment-emergent Adverse Events. | 12 | 13 | 2 | 13 |
The objective response rate (ORR) is used to characterize the activity of acalabrutinib alone or in combination with rituximab in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).
| Percentage of participants | Part 2: Acalabrutinib | Part 2: Acalabrutinib + Rituximab |
|---|---|---|
| Part 2: Investigator Assessed Objective Response Rate (ORR) According to the Lugano Classification for Non-Hodgkin Lymphoma (NHL). | 60.5 (44.4 to 75.0) | 0 (0 to 97.5) |
Treatment-emergent adverse events were used to characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in participants with relapsed/refractory follicular lymphoma (R/R FL).
| Number of participants | Part 3: Acalabrutinib + Rituximab + Lenalidomide 15 mg | Part3: Acalabrutinib + Rituximab + Lenalidomide+20mg |
|---|---|---|
| Part 3: Incidence of Treatment-emergent Adverse Events. | 8 | 21 |
Collected over Treatment-emergent period, i.e. from the first dose of study drug until study discontinuation, 30 days after the last dose of study drug, or one day before the initiation of the subsequent anticancer therapy, whichever occurred earlier, up to 80.7 months for part 1, up to 65.1 months for part 2, and up to 54.3 months for part 3.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| P1: RR Acalabrutinib 100 mg BID | 0/12 (0%) | 2/12 (16.7%) | 12/12 (100%) |
| P1: RR Acalabrutinib 100 mg BID + Rituximab | 1/13 (7.7%) | 5/13 (38.5%) | 13/13 (100%) |
| P1: RR Acalabrutinib 200 mg QD | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| P1: TN Acalabrutinib 100 mg BID + Rituximab | 0/13 (0%) | 3/13 (23.1%) | 13/13 (100%) |
| P2: Acalabrutinib | 7/43 (16.3%) | 9/43 (20.9%) | 41/43 (95.3%) |
| P2: Acalabrutinib + Rituximab | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| P3: Acalabrutinib + Rituximab + Lenalidomide 15 mg | 1/8 (12.5%) | 4/8 (50%) | 8/8 (100%) |
| P3: Acalabrutinib + Rituximab + Lenalidomide 20 mg | 3/21 (14.3%) | 11/21 (52.4%) | 21/21 (100%) |
| Event | P1: RR Acalabrutinib 100 mg BID | P1: RR Acalabrutinib 100 mg BID + Rituximab | P1: RR Acalabrutinib 200 mg QD | P1: TN Acalabrutinib 100 mg BID + Rituximab | P2: Acalabrutinib | P2: Acalabrutinib + Rituximab | P3: Acalabrutinib + Rituximab + Lenalidomide 15 mg | P3: Acalabrutinib + Rituximab + Lenalidomide 20 mg |
|---|---|---|---|---|---|---|---|---|
| SepsisInfections and infestations | 0/12 | 0/13 | 0/2 | 0/13 | 0/43 | 1/1 | 0/8 | 2/21 |
| Covid-19 pneumoniaInfections and infestations | 0/12 | 0/13 | 0/2 | 0/13 | 0/43 | 0/1 | 0/8 | 4/21 |
| PneumoniaInfections and infestations | 1/12 | 0/13 | 0/2 | 0/13 | 1/43 | 0/1 | 0/8 | 3/21 |
| Pneumonia influenzalInfections and infestations | 0/12 | 0/13 | 0/2 | 0/13 | 0/43 | 0/1 | 1/8 | 0/21 |
| DehydrationMetabolism and nutrition disorders | 0/12 | 0/13 | 0/2 | 0/13 | 0/43 | 0/1 | 1/8 | 0/21 |
| AphasiaNervous system disorders | 0/12 | 0/13 | 0/2 | 0/13 | 0/43 | 0/1 | 1/8 | 0/21 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/12 | 0/13 | 0/2 | 0/13 | 1/43 | 0/1 | 1/8 | 0/21 |
| Duodenal ulcerGastrointestinal disorders | 0/12 | 0/13 | 0/2 | 0/13 | 0/43 | 0/1 | 1/8 | 0/21 |
| Covid-19Infections and infestations | 0/12 | 0/13 | 0/2 | 0/13 | 1/43 | 0/1 | 1/8 | 2/21 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/12 | 0/13 | 0/2 | 0/13 | 0/43 | 0/1 | 0/8 | 0/21 |
| Event | P1: RR Acalabrutinib 100 mg BID | P1: RR Acalabrutinib 100 mg BID + Rituximab | P1: RR Acalabrutinib 200 mg QD | P1: TN Acalabrutinib 100 mg BID + Rituximab | P2: Acalabrutinib | P2: Acalabrutinib + Rituximab | P3: Acalabrutinib + Rituximab + Lenalidomide 15 mg | P3: Acalabrutinib + Rituximab + Lenalidomide 20 mg |
|---|---|---|---|---|---|---|---|---|
| Blood creatinine increasedInvestigations | 1/12 | 1/13 | 0/2 | 0/13 | 8/43 | 1/1 | 1/8 | 2/21 |
| Haemoglobin decreasedInvestigations | 0/12 | 0/13 | 0/2 | 0/13 | 0/43 | 1/1 | 0/8 | 0/21 |
| White blood cell count decreasedInvestigations | 0/12 | 0/13 | 0/2 | 1/13 | 0/43 | 1/1 | 0/8 | 3/21 |
| Decreased appetiteMetabolism and nutrition disorders | 2/12 | 3/13 | 0/2 | 1/13 | 4/43 | 1/1 | 1/8 | 4/21 |
| HeadacheNervous system disorders | 7/12 | 5/13 | 0/2 | 6/13 | 15/43 | 1/1 | 3/8 | 8/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/12 | 2/13 | 1/2 | 2/13 | 5/43 | 1/1 | 1/8 | 6/21 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/12 | 1/13 | 0/2 | 1/13 | 4/43 | 1/1 | 0/8 | 1/21 |
| Ingrowing nailSkin and subcutaneous tissue disorders | 0/12 | 0/13 | 0/2 | 0/13 | 0/43 | 1/1 | 0/8 | 0/21 |
| PruritusSkin and subcutaneous tissue disorders | 1/12 | 2/13 | 0/2 | 2/13 | 3/43 | 1/1 | 3/8 | 6/21 |
| UrticariaSkin and subcutaneous tissue disorders | 1/12 | 0/13 | 0/2 | 0/13 | 0/43 | 1/1 | 0/8 | 0/21 |
The All-treated Population, defined as all subjects who received at least 1 dose of study treatment.
| Age, Continuous(Years) | P1: RR Acalabrutinib 100 mg BID | P1: RR Acalabrutinib 100 mg BID + Rituximab | P1: RR Acalabrutinib 200 mg QD | P1: TN Acalabrutinib 100 mg BID + Rituximab | P2: Acalabrutinib | P2: Acalabrutinib + Rituximab | P3: Acalabrutinib + Rituximab + Lenalidomide 15 mg | P3: Acalabrutinib + Rituximab + Lenalidomide 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 63.3 ± 16.0 | 66.7 ± 10.6 | 59.0 ± 21.2 | 59.6 ± 12.2 | 66.0 ± 10.0 | 43.0 ± NA | 62.5 ± 9.7 | 63.0 ± 9.7 | 64.0 ± 11.2 |
| Sex: Female, Male(Participants) | P1: RR Acalabrutinib 100 mg BID | P1: RR Acalabrutinib 100 mg BID + Rituximab | P1: RR Acalabrutinib 200 mg QD | P1: TN Acalabrutinib 100 mg BID + Rituximab | P2: Acalabrutinib | P2: Acalabrutinib + Rituximab | P3: Acalabrutinib + Rituximab + Lenalidomide 15 mg | P3: Acalabrutinib + Rituximab + Lenalidomide 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 8 | 1 | 8 | 17 | 1 | 1 | 6 | 48 |
| Male | 6 | 5 | 1 | 5 | 26 | 0 | 7 | 15 | 65 |
| Race/Ethnicity, Customized(Participants) | P1: RR Acalabrutinib 100 mg BID | P1: RR Acalabrutinib 100 mg BID + Rituximab | P1: RR Acalabrutinib 200 mg QD | P1: TN Acalabrutinib 100 mg BID + Rituximab | P2: Acalabrutinib | P2: Acalabrutinib + Rituximab | P3: Acalabrutinib + Rituximab + Lenalidomide 15 mg | P3: Acalabrutinib + Rituximab + Lenalidomide 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 1 | 1 | 0 | 3 | 3 | 10 |
| Not Hispanic or Latino | 12 | 11 | 2 | 12 | 41 | 1 | 5 | 17 | 101 |
| Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | P1: RR Acalabrutinib 100 mg BID | P1: RR Acalabrutinib 100 mg BID + Rituximab | P1: RR Acalabrutinib 200 mg QD | P1: TN Acalabrutinib 100 mg BID + Rituximab | P2: Acalabrutinib | P2: Acalabrutinib + Rituximab | P3: Acalabrutinib + Rituximab + Lenalidomide 15 mg | P3: Acalabrutinib + Rituximab + Lenalidomide 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asian | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Black or African American | 1 | 0 | 0 | 0 | 4 | 0 | 0 | 2 | 7 |
| Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
| White | 11 | 13 | 2 | 12 | 38 | 1 | 7 | 17 | 101 |
| Region of Enrollment(Participants) | P1: RR Acalabrutinib 100 mg BID | P1: RR Acalabrutinib 100 mg BID + Rituximab | P1: RR Acalabrutinib 200 mg QD | P1: TN Acalabrutinib 100 mg BID + Rituximab | P2: Acalabrutinib | P2: Acalabrutinib + Rituximab | P3: Acalabrutinib + Rituximab + Lenalidomide 15 mg | P3: Acalabrutinib + Rituximab + Lenalidomide 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Canada | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 5 | 9 |
| Italy | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 |
| United States | 12 | 13 | 2 | 13 | 36 | 1 | 8 | 16 | 101 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2014 to primary completion in Aug 2023, 103 months.
Results were first posted in Oct 2025, 2 years 1 month after primary completion.
Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's 103 months is above that.
Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib